Search Results | Blood | American Society of Hematology

1-20 of 200

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study

Hillard Lazarus, Carolina Escobar, MD, Leland Metheny, III, MD, Joseph P. McGuirk, DO, Tsila Zuckerman, MD, Mark Litzow, MD, Scott D. Rowley, MD, Racheli Ofir, PhD, Liran Shani, MD, Jacob M. Rowe, MB, BS

Blood (2020) 136 (Supplement 1): 24–25.

DOI: https://doi.org/10.1182/blood-2020-138662

Published: 2020

Journal Articles

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Jessica K. Altman, MD, Selina M. Luger, MD FRCPC, Olga Frankfurt, MD, Tsila Zuckerman, MD, Jamie L. Koprivnikar, MD, Vamsi Kota, MD, Ashkan Emadi, MD, PhD, Bhavana Bhatnagar, DO, Dale L. Bixby, MD, Micah M. Burch, MD, Ofir Wolach, MD, Itai Levi, MD, Anna Gourevitch, MD, Ron Ram, MD, Liat Flaishon, PhD MD, Shoshi Tessler, PhD, Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MB, BS

Blood (2020) 136 (Supplement 1): 9–10.

DOI: https://doi.org/10.1182/blood-2020-139136

Published: 2020

Journal Articles

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Jessica K. Altman, Tsila Zuckerman, MD, Olga Frankfurt, MD, Selina M. Luger, MD FRCPC, Dale L. Bixby, MD, Vamsi Kota, MBBS, Micah M. Burch, Ofir Wolach, Itai Levi, MD, Anna Gourevitch, Ron Ram, MD, Liat Flaishon, Shoshi Tessler, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe, MB, BS

Blood (2019) 134 (Supplement_1): 179.

DOI: https://doi.org/10.1182/blood-2019-124330

Published: 2019

Journal Articles

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Selina M. Luger, MD FRCPC, Zhuoxin Sun, PhD, Sanam Loghavi, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Martin S. Tallman, MD, Keith W. Pratz, MD, Mark Litzow, MD

Blood (2019) 134 (Supplement_1): 1309.

DOI: https://doi.org/10.1182/blood-2019-128377

Published: 2019

Journal Articles

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Blood (2019) 134 (Supplement_1): 115.

DOI: https://doi.org/10.1182/blood-2019-129876

Published: 2019

Journal Articles

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Chezi Ganzel, MD, Ron Ram, MD, Alexander Gural, MD, Ofir Wolach, MD, Sharon Gino-Moor, MD, Vladimir Vainstein, MD, Boaz Nachmias, MD PhD, Arie Apel, MD, Maya Koren-Michowitz, MD, Oren Pasvolsky, MD, Ronit Yerushalmi, MD, Ivetta Danylesko, Yoseph Cohen, MD, Galit Perets, Yakir Moshe, MD, Miri Zektzer, MD, Shay Yeganeh, MD, Jacob M. Rowe, MB, BS, Yishai Ofran, MD

Blood (2019) 134 (Supplement_1): 5091.

DOI: https://doi.org/10.1182/blood-2019-125662

Published: 2019

Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD

Blood (2019) 134 (Supplement_1): 2662.

DOI: https://doi.org/10.1182/blood-2019-125966

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

Blood (2018) 132 (Supplement 1): 437.

DOI: https://doi.org/10.1182/blood-2018-99-113950

Published: 2018

Journal Articles

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

James M. Foran, MD, Zhuoxin Sun, PhD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, David F. Claxton, MD, Hillard M Lazarus, MD, Daniel A. Arber, MD, Jacob M. Rowe, MD, John Godwin, MD, Yanming Zhang, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Keith W. Pratz, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 3995.

DOI: https://doi.org/10.1182/blood-2018-99-117838

Published: 2018

Journal Articles

Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse

Yishai Ofran, MD, Chezi Ganzel, MD, Shimrit Harlev, MD PhD, Ilana Slouzkey, PhD, Ofrat Beyar Katz, MD, Michal Hayun, PhD, Mira Kharit, MD, Jacob M. Rowe, MD, Avraham Frisch, MD

Blood (2018) 132 (Supplement 1): 5206.

DOI: https://doi.org/10.1182/blood-2018-99-111258

Published: 2018

Journal Articles

The Predictive Value of Thromboelastogram in the Evaluation of Patients with Suspected Acute Venous Thromboembolism

Tareq Abu Assab, MD, David Raveh-brawer, MD, Julia Abramowitz, Mira Naamad, Jacob M. Rowe, MD, Chezi Ganzel, MD

Blood (2018) 132 (Supplement 1): 5052.

DOI: https://doi.org/10.1182/blood-2018-99-119466

Published: 2018

Journal Articles

Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia

Zhaohui Gu, PhD, Michelle L. Churchman, PhD, Kathryn G. Roberts, PhD, Ian Moore, MS, Xin Zhou, PhD, Joy Nakitandwe, PhD, Kohei Hagiwara, MD, Stephane Pelletier, PhD, Sebastian Gingras, PhD, Hartmut Berns, PhD, Debbie Payne-Turner, Ashley Hill, BS, Ilaria Iacobucci, PhD, Lei Shi, PhD, Stanley Pounds, PhD, Cheng Cheng, PhD, Deqing Pei, MS, Chunxu Qu, PhD, Meenakshi Devidas, PhD, Yunfeng Dai, PhD, Shalini C. Reshmi, PhD, Julie Gastier Foster, PhD, Elizabeth A. Raetz, MD, Michael J. Borowitz, MD PhD, Brent Wood, MD PhD, William L. Carroll, MD, Patrick Zweider McKay, MD PhD, Karen R. Rabin, MD PhD, Leonard A. Mattano, MD, Kelly W. Maloney, MD, Alessandro Rambaldi, MD PhD, Orietta Spinelli, PhD, Jerald Radich, MD, Mark D. Minden, MD PhD, Jacob M. Rowe, MD, Selina Luger, MD, Mark R. Litzow, MD, Martin S. Tallman, MD, Janis Recevskis, PhD, Yanming Zhang, Ravi Bhatia, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MDPhD, Clara D. Bloomfield, MD, Wendy Stock, MD, Steven M. Kornblau, MD, Hagop M. Kantarjian, MD, Marina Y. Konopleva, MD PhD, William E. Evans, PharmD, Sima Jeha, MD, Ching-Hon Pui, MD, Jun J. Yang, PhD, Elisabeth M. Paietta, PhD, James R. Downing, MD, Mary V Relling, PharmD, Jinghui Zhang, Mignon L. Loh, MD, Stephen P. Hunger, MD, Charles G. Mullighan, MBBS, MD

Blood (2018) 132 (Supplement 1): 565.

DOI: https://doi.org/10.1182/blood-2018-99-111219

Published: 2018

Journal Articles

Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation

Hillard M Lazarus, MD, Leland Metheny, MD, Tsila Zuckerman, MD, Carolina Escobar, MD, Joseph P. McGuirk, DO, Yael Rosen, MD, Jacob M. Rowe, MD

Blood (2018) 132 (Supplement 1): 3379.

DOI: https://doi.org/10.1182/blood-2018-99-116239

Published: 2018

Journal Articles

Results of a Non-Interventional Clinical Trial of Apograft — a Novel Technology for GvHD Prevention

Jerry Stein, MD, Tsila Zuckerman, MD, Yuval Baar, Hila Wildbaum, Tamar Katz, Michal Perl-Yaffe, Limor Horev-Azaria, Shai Yarkoni, MD PhD, Amotz Nechushtan, Galina Rodionov, Liron Gez, Michal Rosenzwaig, Anastasia Rodin, Yaron Pereg, John F DiPersio, MD PhD, Jacob M. Rowe, MD, Isaac Yaniv, MD

Blood (2017) 130 (Supplement 1): 4445.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4445.4445

Published: 2017

Journal Articles

Ibrutinib: A Risk Factor for Invasive Fungal Infections?

Blood (2017) 130 (Supplement 1): 4323.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4323.4323

Published: 2017

Journal Articles

Prospective Study of Acute Myeloid Leukemia (AML) Clinical Epidemiology and Cytogenetic Risk Group in Older Adults in the ECOG-ACRIN E2906 Clinical Trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) Study

Blood (2017) 130 (Supplement 1): 2579.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2579.2579

Published: 2017

Journal Articles

Graft-Vs-Leukemia Effect in Acute Lymphoblastic Leukemia: Mild Acute Graft-Vs-Host Disease Protects Against Relapse and Improves Survival after Allogeneic Transplantation: A CIBMTR Analysis

Moshe Yeshurun, Daniel J. Weisdorf, MD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Mary E. Flowers, MD, Marcos De Lima, MD, Jacob M. Rowe, MD, Brenda M. Sandmaier, MD, Martin S. Tallman, MD, Michael R Verneris, MD, Veronika Bachanova, MD PhD

Blood (2017) 130 (Supplement 1): 518.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.518.518

Published: 2017

Journal Articles

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Tsila Zuckerman, MD, Ron Ram, MD, Maya Koren-Michowitz, MD, Luiza Akria, MD, Ron Hoffman, Israel Henig, MD, Yishai Ofran, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Shay Yeganeh, MD, Stela Gengrinovitch, PhD, Liat Flaishon, PhD MD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MD

Blood (2017) 130 (Suppl_1): 893.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.893.893

Published: 2017

Journal Articles

Published abstracts at international meetings often over- or underestimate the initial response rate

Clinical Trials & Observations

Ofrat Beyar-Katz, Jacob M. Rowe, Lauren E. Townsend, Martin S. Tallman, Rivka Hadomi, Netanel A. Horowitz

Blood (2017) 129 (16): 2326–2328.

DOI: https://doi.org/10.1182/blood-2017-01-763144

Published: 2017

Includes: Supplemental data

Journal Articles

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Clinical Trials & Observations

Blood (2017) 129 (13): 1763–1767.

DOI: https://doi.org/10.1182/blood-2016-10-747170

Published: 2017

2 3 4 5

NARROW

Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse

The Predictive Value of Thromboelastogram in the Evaluation of Patients with Suspected Acute Venous Thromboembolism

Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia

Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation

Results of a Non-Interventional Clinical Trial of Apograft — a Novel Technology for GvHD Prevention

Ibrutinib: A Risk Factor for Invasive Fungal Infections?

Prospective Study of Acute Myeloid Leukemia (AML) Clinical Epidemiology and Cytogenetic Risk Group in Older Adults in the ECOG-ACRIN E2906 Clinical Trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) Study

Graft-Vs-Leukemia Effect in Acute Lymphoblastic Leukemia: Mild Acute Graft-Vs-Host Disease Protects Against Relapse and Improves Survival after Allogeneic Transplantation: A CIBMTR Analysis

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Published abstracts at international meetings often over- or underestimate the initial response rate

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only